J C Nossent1. 1. Department of Medicine, St. Elisabeth Hospital, Willemstad, Curaçao, Netherlands Antilles.
Abstract
OBJECTIVE: To apply the recently described Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR-DI) in a well defined cohort of patients with systemic lupus erythematosus (SLE) and to study its association with disease activity, corticosteroid therapy, and prognosis. METHODS: We conducted a record review of 90 patients with SLE followed at a single center for a mean period of 6 years with periodic evaluations of SLE Disease Activity Index (SLEDAI), cumulative damage according to SLICC/ACR-DI, and therapy. Overall disease activity during the disease course was calculated as weighted averages of SLEDAI (WAS). RESULTS: Mean SLICC/ACR-DI was 0.6 six months after diagnosis and increased to 2.4 at last assessment. Thirteen patients (14%) remained free of accumulated damage at last visit. Index scores showed significant correlations with WAS scores and the number of disease exacerbations (SLEDAI > 10), but not with age, mean daily, or cumulative corticosteroid dosage. High WAS scores were independently associated with poorer survival, but SLICC/ACR-DI scores were not. CONCLUSION: SLICC/ACR-DI scores correlate with overall disease activity, but not with length or intensity of corticosteroid therapy. While easily applicable, its prognostic value is subordinate to that of persistent disease activity.
OBJECTIVE: To apply the recently described Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR-DI) in a well defined cohort of patients with systemic lupus erythematosus (SLE) and to study its association with disease activity, corticosteroid therapy, and prognosis. METHODS: We conducted a record review of 90 patients with SLE followed at a single center for a mean period of 6 years with periodic evaluations of SLE Disease Activity Index (SLEDAI), cumulative damage according to SLICC/ACR-DI, and therapy. Overall disease activity during the disease course was calculated as weighted averages of SLEDAI (WAS). RESULTS: Mean SLICC/ACR-DI was 0.6 six months after diagnosis and increased to 2.4 at last assessment. Thirteen patients (14%) remained free of accumulated damage at last visit. Index scores showed significant correlations with WAS scores and the number of disease exacerbations (SLEDAI > 10), but not with age, mean daily, or cumulative corticosteroid dosage. High WAS scores were independently associated with poorer survival, but SLICC/ACR-DI scores were not. CONCLUSION: SLICC/ACR-DI scores correlate with overall disease activity, but not with length or intensity of corticosteroid therapy. While easily applicable, its prognostic value is subordinate to that of persistent disease activity.
Authors: Meggan Mackay; Mathew P Bussa; Cynthia Aranow; Aziz M Uluğ; Bruce T Volpe; Patricio T Huerta; Miklos Argyelan; Arthur Mandel; Joy Hirsch; Betty Diamond; David Eidelberg Journal: Mol Med Date: 2011-09-21 Impact factor: 6.354
Authors: Karen H Costenbader; Munther Khamashta; Silvia Ruiz-Garcia; Maria Teresa Perez-Rodriguez; Michelle Petri; Jennifer Elliott; Susan Manzi; Elizabeth W Karlson; Tabitha Turner-Stokes; Bonnie Bermas; Jonathan Coblyn; Elena Massarotti; Peter Schur; Patricia Fraser; Iris Navarro; John G Hanly; Timothy S Shaver; Robert S Katz; Eliza Chakravarty; Paul R Fortin; Martha L Sanchez; Jigna Liu; Kaleb Michaud; Graciela S Alarcón; Frederick Wolfe Journal: Arthritis Care Res (Hoboken) Date: 2010-04 Impact factor: 4.794
Authors: G S Alarcón; J Calvo-Alén; G McGwin; A G Uribe; S M A Toloza; J M Roseman; M Fernández; B J Fessler; L M Vilá; C Ahn; F K Tan; J D Reveille Journal: Ann Rheum Dis Date: 2006-09 Impact factor: 19.103
Authors: Sarah Al Sawah; Xiang Zhang; Baojin Zhu; Laurence S Magder; Shonda A Foster; Noriko Iikuni; Michelle Petri Journal: Lupus Sci Med Date: 2015-03-11